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that are practiced in the hemodinamy service in the Cardiology
Hospital “Centro Nacional Siglo XXI” in Mexico City.
METHODS: Identiﬁcation of resource use at the hemodinamy
service was realized through expert opinion and the revision of
hospital records during the ﬁrst two months of 2005. Unitary
costs were obtained from the Accounting Department of the hos-
pital. The intervention’s cost estimation was realized with the
technique “case mix” and the perspective was that of the Social
Security Mexican Institute (IMSS). The direct medical costs
included: material of high specialty, medical instruments, drugs,
cineﬂuorscopy and human resources. Indirect medical costs
included: equipment, depreciation, laundry, electricity, tele-
phone, water, etc. Within the estimations of the interventions it
was included the use of counterpulsation balloon, cutting
balloon, glucoproteins (tiroﬁban or abciximab) and trombec-
tomy. RESULTS: Diagnostic catheterism was estimated in
US$328.7. The cost of the other interventions shifted in function
of the type of the stent used (conventional or medical). Inter-
vention of one vessel with conventional stent resulted in
US$1182.5; and with medical stent this raised to US$3438.5.
Also, intervention costs of one vessel trombectomy + counter-
pulsation balloon + glucoproteins inhibitors resulted in
U$7508.1. An intervention with two left vessel was calculated
in US$10,910.2 and with two left vessel and one right vessel, the
cost increased to US$13,706.7. CONCLUSIONS: Our study
results showed high direct medical costs heterogeneity on diag-
nostic procedures in a Mexican hemodinamy service. These
results are useful for cost containment policies and for further
health economics researches in Mexico.
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INPATIENT MANAGEMENT OF TRANSMURAL AND
SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION
(AMI): DIFFERENCES IN RESOURCE USE AND COST
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OBJECTIVES: To identify number of transmural and subendo-
cardial AMI cases, as well as related inpatient resource use and
cost by type of AMI. METHODS: Reported all-payer 2003 
hospital data from six states (CA, FL, MD, MA, TX, WA) were
analyzed. Transmural (410.00–410.60, 410.01–410.61) and
subendocardial (410.70, 410.71) AMI cases were identiﬁed using
ICD-9 principal diagnosis codes. AMI cases with other (410.80,
410.81) or unspeciﬁed (410.90, 410.91) codes were identiﬁed,
but excluded. Demographics, length of stay, admission source,
AMI location, secondary diagnosis and procedure codes, DRG
assignment, disposition status and reported charges were ana-
lyzed. Charges (accommodations, ancillary services) adjusted by
a 0.65 cost-to-charge ratio, and for medical inﬂation and geo-
graphic factors to reﬂect national values are reported as costs
(2005US$). RESULTS: Of the 168,831 AMI cases identiﬁed,
more than half (56%) were coded as subendocardial (n =
94,625). Transmural AMI was coded for 35% (n = 59,123); 9%
were coded as other or unspeciﬁed AMI. The subendocardial
AMI group had more females (47% vs. 40%), was older (mean
age: 72, median: 75 years vs. mean: 68, median: 70 years), and
had a slightly longer LOS (mean: 5.8, median: 4 days vs. mean:
5.5, median: 3.7 days), on average, than those with a transmural
AMI. Signiﬁcantly (p < 0.01) fewer patients with subendocardial
AMI had ICU days (50% vs. 75%), and percutaneous coronary
(47% vs. 27%) and stent (8% vs. 6%) procedures. Coronary-
bypass surgery rate was the same (10%) for both groups. Inpa-
tient case fatality rate was signiﬁcantly (p < 0.01) higher for
transmural group (10% vs. 7%). The average cost per stay for
transmural AMI was $34,012 (median: $23,880); $28,483
(median: $18,664) for subendocardial AMI. CONCLUSIONS:
Substantially fewer cases of acute transmural infarct were
reported in this dataset. Yet, when reported, they were 
more lethal, resource intensive and costly than a subendocardial
AMI.
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OBJECTIVE: DVT is an important problem in clinical practice.
This study aims to estimate the costs of treatment of DVT from
the perspective of the private medicine payers in Brazil.
METHODS: To determine actual costs of patient management
the resource use collected during comparative clinical trials often
is insufﬁcient. Although large data bases can be used to estimate
patient health care resource consumption they are not always
available. One reasonable data source is soliciting expert opinion
from clinicians. Two Delphi panels one for vascular surgeons,
and another for intensivists were performed in order to delineate
practice patterns and to obtain resource utilization for routine
treatment and monitoring, adverse event management and other
clinical parameters representative of community physicians man-
aging of DVT. Responses were obtained from seven vascular sur-
geons and ﬁve intensivists from various centers in Brazil with
experience of treating DVT. Percentage likelihood of complica-
tions due to thromboprophylaxis was determined based upon
physician consensus. A decision analytic model was designed to
project the costs associated with venous thromboembolism.
RESULTS: The detected mean cost (in Brazilian Reais) of DVT
was R$9895.23. The detected cost of diagnosing DVT was
R$74.01, the treatment cost without considering itxs complica-
tions was R$5208.76 and the complications cost, balanced by
incidence was R$4612.46. The cost to avoid a DVT by the use
of a thromboprophylaxis was R$177.68. CONCLUSIONS:
DVT costs are only a part of the costs incurred in treating high
risk surgical or clinical patients. These results clearly show the
substantial costs that a DVT may represent in the treatment 
of these patients that may be prevented by the use of 
thromboprophylaxis.
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OBJECTIVES: This study was designed to investigate how
African American patients respond to DTCA of prescription
drug Lipitor® and the relationships between potential inﬂuenc-
ing variables and patients’ responses. METHODS: Face-to-face
interview was employed for this study, and a convenience sample
consisting of 160 African American patients were interviewed at
a general medicine clinic in a public hospital. Short-Test of Func-
tional Health Literacy in Adults (S-TOFHLA) was administered
to all study participants. Then the participants were asked to
view a TV advertisement of Lipitor®, followed by DTCA-related
interviews. Patients’ demographic and socioeconomic informa-
tion was also collected during the interviews. Bivariate analyses
and logistic regressions were used to assess the relationships
between potential inﬂuencing variables and patients’ responses
